Antibody-Drug Conjugates in NSCLC and SCLC
DOI:
https://doi.org/10.54097/vpn7ym28Keywords:
Non-small cell lung cancer; small cell lung cancer; Antibody-drug couplings; monoclonal antibodies.Abstract
Lung cancer, the most prevalent type of cancer, would likely account for 1.8 million cancer deaths (18%) worldwide in 2020. Non-small cell lung cancer (NSCLC) is more common in clinically diagnosed patients, whereas small cell lung cancer (SCLC) is less common but typically develops more quickly. However, traditional treatment methods, such as surgery, adjuvant chemoradiotherapy, have their limitations. Antibody-drug couplings (ADCs), one of the fastest growing cancer drugs of late, use exclusive binding of their monoclonal antibodies (Mabs) to the surface antigens of cancer cells to precisely deliver anti-cancer drugs to target cancer cells. ADC, which specifically targets cancer cells while preserving healthy ones, is a promising cancer treatment. Five ADCs approved by the FDA for solid malignancies, while numerous ADCs targeting NSCLC and SCLC are globally in number of clinical trials. This article reviews the therapeutic use of ADC in non-small cell lung cancer and small cell lung cancer. Develop an understanding of the mechanisms and clinical effects of ADCs.
Downloads
References
Rosner, S., et al. (2023). Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. American Society of Clinical Oncology Educational Book, 43, e389968.
Li, B. T., et al. (2022). Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer. New England Journal of Medicine, 386(3), 241–251.
Iwata, H., et al. (2018). Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts. Journal of Clinical Oncology, 36(15_suppl), 2501–2501.
Janne, P. A., et al. (2022). Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC. Journal of Clinical Oncology, 40(16_suppl), TPS3161–TPS3161.
Yu, H. A., et al. (2023). HERTHENA-Lung01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC. Future Oncology, 19(19), 1319–1329.
Okajima, D., et al. (2021). Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Molecular Cancer Therapeutics, 20(12), 2329–2340.
Levy, B. P., et al. (2023). TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncology.
Titmarsh, H. F., et al. (2020). The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy. Frontiers in Oncology, 10.
Strickler, J. H., et al. (2018). First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 36(33), 3298–3306.
Camidge, D. R., et al. (2023). Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 41(5), 1105–1115.
Blackhall, F., et al. (2021). Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. Journal of Thoracic Oncology, 16(9), 1547–1558.
Bardia, A., et al. (2021). Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Annals of Oncology, 32(6), 746–756.
Morgensztern, D., et al. (2023). First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer. Journal of Clinical Oncology, 41(16_suppl), 3002–3002.
Qiu, M., et al. (2021). The Expression of Three Negative Co-Stimulatory B7 Family Molecules in Small Cell Lung Cancer and Their Effect on Prognosis. Frontiers in Oncology, 11.
Abrams, T., et al. (2018). Preclinical Antitumor Activity of a Novel Anti–c-KIT Antibody–Drug Conjugate against Mutant and Wild-type c-KIT–Positive Solid Tumors. Clinical Cancer Research, 24(17), 4297–4308.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
